Latest Biotech News

Wave Life Sciences’ Wave-007 update triggered a sharp selloff after the company reported mixed early-stage obesity data in its Phase I INLIGHT trial. Investors focused on a less than 1%...

Biogen’s litifilimab gained traction with new Phase 2 lupus readouts, with the company reporting improvements in another trial and building toward potential pivotal data. The latest results add to...

Merck said it is leaning toward a lower Winrevair dose in a pivotal Phase 3 trial for a rare form of heart failure after observing a “pretty profound” benefit at the lowest dose in its earlier...

Revvity Signals described how AI is being used to manage the growing review burden in late-stage clinical development, arguing that automation is becoming necessary as Phase III trials generate...

Insilico Medicine and Eli Lilly inked a commercialization agreement for some of Insilico’s preclinical AI-discovered oral therapeutics, with economics tied to regulatory and commercial milestones....

Kailera Therapeutics, which has raised one of the largest rounds of 2025, is planning an IPO to fund advancement of its obesity pipeline through the clinic. The planned public offering comes as...

The Josep Carreras Leukaemia Research Institute and China’s Institute of Hematology & Blood Diseases Hospital (IHCAMS) under the Chinese Academy of Medical Sciences and Peking Union Medical...

Researchers at the University of Manchester won nearly £1 million from UK Research and Innovation to build snail-inspired soft microrobots for precision anti-cancer drug delivery in bowel cancer....

Revvity Signals CEO Simone Sharma says Phase III trials are generating millions of data points, while the industry’s approval output has not kept pace with R&D spend, pushing sponsors to rethink...

Wave Life Sciences’ obesity candidate WVE-007 triggered a sharp investor selloff after early Phase I INLIGHT data showed placebo-adjusted weight changes that fell short of what investors appeared...

Insilico Medicine and Eli Lilly expanded their strategic deal for AI-discovered oral therapeutics, with terms described as $115 million up front and up to about $2.75 billion in “biobucks” tied to...

Merck is adjusting its Phase 3 strategy for Winrevair after Phase 2 results suggested the most favorable effect occurred at the lowest dose tested. The report says Merck is leaning toward a lower...

Biogen reported Phase 2 success for litifilimab, an anti-BDCA2 antibody, as it looks to build immunology momentum around lupus. The company said the treatment improved skin lesions at 24 weeks,...

Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1, an inherited immunodeficiency that can be fatal in infancy and early childhood....

Kailera Therapeutics is plotting an IPO to raise additional capital for its obesity portfolio, following one of biotech’s biggest fundraisings in 2025. The report frames the move as a way to push...

Kailera Therapeutics is seeking to go public as it looks to fund its obesity pipeline after raising heavily in 2025, according to the report. The company’s intent is to secure further financing to...

BioNTech’s leadership outlined how the company built its platform and grew into global recognition long before its COVID-era breakthrough. Holger Kissel, SVP scientific relations & liaison at...

Everlywell and Jona announced a partnership to expand access to Jona’s gut microbiome test through Everlywell’s consumer platform. The deal is positioned as a distribution expansion, moving...

Rocket Pharmaceuticals won an FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1), an ultra-rare inherited immunodeficiency that can be fatal in infancy. The...

Merck signaled a pivot in its Phase 3 development plan for Winrevair (improved benefit at the lowest dose in Phase 2) by steering toward a lower dose for a pivotal trial in an uncommon form of...